108 related articles for article (PubMed ID: 21103845)
1. Lower limbs erosions induced by sunitinib.
Kluger N; Chapelle A; Jacot W; Guillot B
Acta Derm Venereol; 2011 May; 91(3):360-1. PubMed ID: 21103845
[No Abstract] [Full Text] [Related]
2. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
3. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
4. Fatigue with sunitinib-induced hypothyroidism.
Senior K
Lancet Oncol; 2007 Feb; 8(2):101. PubMed ID: 17288042
[No Abstract] [Full Text] [Related]
5. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
7. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
8. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
9. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.
Nicholaou T; Wong R; Davis ID
Lancet; 2007 Jun; 369(9577):1923-4. PubMed ID: 17560435
[No Abstract] [Full Text] [Related]
10. Sunitinib and hypothyroidism.
Wolter P; Dumez H; Schöffski P
N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
[No Abstract] [Full Text] [Related]
11. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.
Diekstra MH; Belaustegui A; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; García-Donas J; Rodríguez-Antona C; Rini BI; Guchelaar HJ
Pharmacogenomics J; 2017 Jan; 17(1):42-46. PubMed ID: 26810136
[TBL] [Abstract][Full Text] [Related]
12. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
[No Abstract] [Full Text] [Related]
13. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
14. Sunitinib as adjuvant therapy for renal cell carcinoma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
[No Abstract] [Full Text] [Related]
15. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
[No Abstract] [Full Text] [Related]
16. [Necrotizing hand-foot skin reaction induced by antiangiogenic in a patient with Thevenard neuroacropathy].
Durant C; Saint-Jean M; Connault J; Pistorius MA; Planchon B
J Mal Vasc; 2009 May; 34(3):222-5. PubMed ID: 19359111
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
18. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
Khan KH; Fenton A; Murtagh E; McAleer JJ; Clayton A
Tumori; 2012; 98(5):139e-142e. PubMed ID: 23235770
[TBL] [Abstract][Full Text] [Related]
19. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
Rodríguez-Reimúndes E; Perazzo F; Vilches AR
Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
[TBL] [Abstract][Full Text] [Related]
20. Severe epistaxis with tyrosine kinase inhibitors.
Hall PS; Kancherla K; Sastry PS; Brown JE
Clin Oncol (R Coll Radiol); 2008 May; 20(4):318-9. PubMed ID: 18353621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
